Evidence map›Paper›PMID 25989018›Full record

ArticleJournal of biomedical informatics2015

Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.

Andreas N Strobl, Andrew J Vickers, Ben Van Calster, Ewout Steyerberg, Robin J Leach, Ian M Thompson, Donna P Ankerst

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of biomedical informatics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Liquid Biopsy Potential Biomarkers in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Andreas N StroblTU München, Department of Mathematics, Munich, Germany; HelmholtzZentrum München, Institute of Computational Biology, Munich, Germany. Electronic address: a.strobl@tum.de.
Andrew J VickersMemorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York City, NY, USA.
Ben Van CalsterKU Leuven, Department of Development and Regeneration, Leuven, Belgium.
Ewout SteyerbergErasmus MC, Department of Public Health, Rotterdam, The Netherlands.
Robin J LeachUniversity of Texas Health Science Center at San Antonio, Department of Cellular and Structural Biology, San Antonio, TX, USA; University of Texas Health Science Center at San Antonio, Department of Urology, San Antonio, TX, USA.
Ian M ThompsonUniversity of Texas Health Science Center at San Antonio, Department of Urology, San Antonio, TX, USA.
Donna P AnkerstTU München, Department of Mathematics, Munich, Germany; HelmholtzZentrum München, Institute of Computational Biology, Munich, Germany; University of Texas Health Science Center at San Antonio, Department of Urology, San Antonio, TX, USA; University of Texas Health Science Center at San Antonio, Department of Epidemiology and Biostatistics, San Antonio, TX, USA.
The University of Texas Health Science Center at San Antonio · USErasmus MC · NLHelmholtz Zentrum München · DEKU Leuven · BEMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CAU01CA086402 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LEACH, ROBIN JEAN, THOMPSON, IAN M. · 2000 to 2018
$33.1M
Oxidative Damage and DNA Repair in the PCPTP01CA108964 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, IAN M · 2005 to 2009
$13.6M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
Dynamic, multi-cohort prediction modeling of prostate biopsy outcomeR01CA179115 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ANKERST, DONNA PAULER, VICKERS, ANDREW J · 2014 to 2018
$2.3M
NCI NIH HHS 5P30 CA0541474-19NCI NIH HHS P01 CA108964NCI NIH HHS P01 CA108964-06NCI NIH HHS P30 CA008748NCI NIH HHS P30-CA008748NCI NIH HHS P30 CA054174NCI NIH HHS P50 CA092629NCI NIH HHS P50-CA92629NCI NIH HHS R01 CA179115NCI NIH HHS R01CA179115NCI NIH HHS U01 CA086402NCI NIH HHS U01CA86402NCI NIH HHS UM1 CA18288NCI NIH HHS UM1 CA182883
6 · The paper itself

Abstract

Clinical risk calculators are now widely available but have generally been implemented in a static and one-size-fits-all fashion. The objective of this study was to challenge these notions and show via a case study concerning risk-based screening for prostate cancer how calculators can be dynamically and locally tailored to improve on-site patient accuracy. Yearly data from five international prostate biopsy cohorts (3 in the US, 1 in Austria, 1 in England) were used to compare 6 methods for annual risk prediction: static use of the online US-developed Prostate Cancer Prevention Trial Risk Calculator (PCPTRC); recalibration of the PCPTRC; revision of the PCPTRC; building a new model each year using logistic regression, Bayesian prior-to-posterior updating, or random forests. All methods performed similarly with respect to discrimination, except for random forests, which were worse. All methods except for random forests greatly improved calibration over the static PCPTRC in all cohorts except for Austria, where the PCPTRC had the best calibration followed closely by recalibration. The case study shows that a simple annual recalibration of a general online risk tool for prostate cancer can improve its accuracy with respect to the local patient practice at hand.

Indexed as

AdultAgedAged, 80 and overAlgorithmsAustriaBayes TheoremBiopsyCalibrationCohort StudiesDatabases, FactualEnglandHumansLogistic ModelsMaleMiddle AgedProstate-Specific AntigenProstate-Specific AntigenCalibrationDiscriminationLogistic regressionPredictionProstate cancerRevision

Identifiers

PMID25989018
PMCPMC4532612
OpenAlexW1914974178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.